US FDA Advisory Cmte. To Evaluate Terlipressin's Clinical Outcomes, Risk Of Respiratory Failure

Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.

Human Body Organs Anatomy (Liver)
Mallinckrodt drug to treat life-threatening hepatorenal syndrome gets advisory committee review • Source: Shutterstock

Mallinckrodt plc's terlipressin for hepatorenal syndrome, a life-threatening condition involving acute kidney failure in people with cirrhosis, has had a difficult path at the US Food And Drug Administration and may face more hurdles as it goes before an advisory committee.

Following a complete response letter in 2009, the sponsor had to conduct two additional clinical trials. The agency has questions...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers